John Riis Mortensen

Zoetis Denmark ApS designs and manufactures diagnostic cartridges based on micro fluidic technology. Its technology enables veterinarians to obtain critical diagnostic information on their patients. The company was founded in 2000 and is headquartered in Farum, Denmark.

LiPlasome Pharma A/S develops, produces and supplies drugs for chemotherapy treatment. It has developed a technology based on incapsulation of chemotherapy in liposomes (fatty molecules) that will only dissolve in and around cancer tissue (tumors or metastases). The firm’s technology will improve chemotherapy treatment within a wide range of cancer diseases significantly as it improves the balance between effect and side effects. LiPlasome’s first drug candicate LiplaCis which is a liposonal formulation of Cisplatin, is in clinical phase 1. The company was founded in January 2001 by Ole Gunner Mouritsen and is headquartered in Hoersholm, Denmark.

Vivostat A/S provides cardiac, thoracic and orthopaedic surgery medical devices. It offers vivostat system, an automated system for the on-site preparation and application of patient-derived fibrin sealant or platelet rich fibrin. Its products include Vivostat autologous fibrin sealant for various settings in surgical areas, transfusion centers, or blood banks and Vivostat platelet rich fibrin, which utilizes the patient's own blood to derive either a surgical sealant to prevent and stop bleedings, or a gel with a high concentration of growth factors that stimulates the healing of chronic wounds, as well as provides application devices. The compnay was founded in 2001 by Tom Bjerg Lauritzen and Niels Hvid and is headquartered in Alleroed, Denmark.

Vecata Invest A/S (Vecata) is a venture capital firm wholly-owned by the Bagger-Sorensen family. The firm was established in 2003 and is headquartered in Vejle, Denmark.

Bagger-Sørensen & Co. A/S is a Danish company based in Vejle, Denmark. Bagger-Sørensen & Co. A/S develops and manufactures medical chewing gum. The company was founded in 1915, and Hans-Henrik Horsted Eriksen has been the CEO of the company since 2015.

CellCure A/S manufactures organic chemical products. It focuses on the cultivation of human tumor-specific killer T lymphocytes with immunotherapeutic treatment of cancer. The company was founded in 2000 by Keld Kaltoft and is headquartered in Copenhagen, Denmark.

Fluxome, a Copenhagen-based Danish company, is a recognized leader in the field of industrial biotechnology. Fluxome uses its proprietary, cutting-edge microbial metabolic engineering technology platform to build highly efficient cell factories for the production of a broad range of commercially important nutraceutical ingredients. Fluxome's technology allows the company to rapidly develop and commercialize high purity, natural products manufactured using cost-effective bioprocesses.

Anapa Biotech A/S provides molecular tools to enhance the performance of natural nucleic acids. Its technology is the proprietary Twisted Intercalating Nucleic Acid molecules. The company was founded by Gorm Lisby and Henrik Westh in 2002 and is headquartered in Hørsholm, Denmark.

Mirrx Therapeutics A/S provides protein production technology. Its technology Blockmirs, is steric antisense blockers that bind to specific microRNA binding sites in target RNAs to thereby prevent microRNA binding to the same site. The company was founded by Hans Thorleif Møller on July 1, 2009 and is headquartered in Vejle, Denmark.